ArticleMolecular oncology2018
GeneExpressScore Signature: a robust prognostic and predictive classifier in gastric cancer.
Article in Molecular oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Systematic Review of Prognostic Gene Signature in Gastric Cancer Patients.Frontiers in bioengineering and biotechnology · 2020Pooled it
- Tumor Immune Contexture Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer.The journal of gene medicine · 2025Article
- Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer.Fundamental research · 2024Article
- PreoperativeQuantitative imaging in medicine and surgery · 2023Article
- Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer.Gland surgery · 2023Article
- Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.Journal of translational medicine · 2023Article
- A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2022Article
- Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.Cancer medicine · 2021Article
- Identification of an EMT-Related Gene Signature for Predicting Overall Survival in Gastric Cancer.Frontiers in genetics · 2021Article
- The prediction of survival in Gastric Cancer based on a Robust 13-Gene Signature.Journal of Cancer · 2021Article
- A Nomogram Combining a Four-Gene Biomarker and Clinical Factors for Predicting Survival of Melanoma.Frontiers in oncology · 2021Article
- Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature.Journal of translational medicine · 2020Article
- A transcriptomic study for identifying cardia- and non-cardia-specific gastric cancer prognostic factors using genetic algorithm-based methods.Journal of cellular and molecular medicine · 2020Article
- Prognostic and Predictive Value of a Long Non-coding RNA Signature in Glioma: A lncRNA Expression Analysis.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several prognostic signatures have been developed for gastric cancer (GC), the utility of these tools is limited in clinical practice due to lack of validation with large and multiple independent cohorts, or lack of a statistical test to determine the robustness of the predictive models. Here, a prognostic signature was constructed using a least absolute shrinkage and selection operator (LASSO) Cox regression model and a training dataset with 300 GC patients. The signature was verified in three independent datasets with a total of 658 tumors across multiplatforms. A nomogram based on the signature was built to predict disease-free survival (DFS). Based on the LASSO model, we created a GeneExpressScore signature (GES
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.